Clinical pharmacy services in hematology can have a significant impact, and the Pharmacy Times® Hematology resource center provides clinical news and articles about the topic. Here, visitors will find information about upcoming hematology conferences and meetings, updated clinical trial listings, and other resources.
The BTD designations for asciminib were based on the phase 3, multicenter, open-label, randomized ASCEMBL trial and a phase I trial that included patients with Ph+ CML, some of them harboring the T315I mutation.
Patients with AML that has gone into remission following initial chemotherapy were found to remain in remission longer and have improved OS if they took a pill form of azacitidine as a maintenance treatment.
Daniel Wojenski, PharmD, discusses use of BTK inhibitors, primarily ibrutinib, as monotherapy vs in combination therapies as frontline treatment for CLL.
The Pharmacy Times® Hematology specialty page serves as a hub for all clinical news and articles related to hematological conditions. The coverage includes updates from the floor of all the biggest societal conferences and annual meetings, like the American Society of Hematology Annual Meeting, as well as video interviews of the leading hematologists and key opinion leaders in the space.